Cargando…

Impact of early use of long acting paliperidone (1 and 3 monthly) in a first-episode psychosis sample

INTRODUCTION: Relapse prevention is a key objetive for patients with a First Episode Psychosis (FEP) and the low adherence to antipsychotic (AP) treatment is the main reason for relapse after a FEP. OBJECTIVES: There are no clear recommendations about the early use of long-acting injectables (LAIs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez, P. Gil, Rodriguez, J.M., Fernandez, L. Garcia, Martin, E. Fernandez, Gayoso, N. Fernandez, Estevez, V. Sanchez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480272/ http://dx.doi.org/10.1192/j.eurpsy.2021.2144

Ejemplares similares

Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis
por: Lopez, P. Gil, et al.
Publicado: (2021)

Paliperidone induced sinus tachycardia in a patient with first episode of psychosis (FEP)
por: Sarafopoulos, A., et al.
Publicado: (2021)

Course of the Metabolic Syndrome (Mets) in a First Episode Psychosis Sample
por: Garcia De Jalon, E., et al.
Publicado: (2022)

Alternative initiation regimen of paliperidone palmitate long-acting injectable
por: Menendez Gil, I.E., et al.
Publicado: (2022)

Paliperidone induced neutropenia in first episode psychosis: a case report
por: Martos, Natalie, et al.
Publicado: (2021)

PM383. Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER
por: Chung, Young-Chul
Publicado: (2016)

Alternative initiations with 6-monthly paliperidone palmitate. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

PM416. Efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic: off-label use in first-episode adolescent schizophrenic patients
por: Petrić, Daniela, et al.
Publicado: (2016)

PALIPERIDONE PALMITATE 6-MONTH FORMULATION FOR THE TREATMENT OF SCHIZOPHRENIA: A 4-MONTH FOLLOW-UP STUDY
por: Romero Guillena, S. L., et al.
Publicado: (2023)

Clinical experiences with 6-monthly paliperidone palmitate after 12 months of use. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Psychopathological networks in psychosis and changes over time: A long-term cohort study of first-episode psychosis
por: Gil-Berrozpe, G., et al.
Publicado: (2022)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Diagnostic change 2 years after a first episode of psychosis
por: Aranguren, L., et al.
Publicado: (2021)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Role of migration in the development of a first episode of psychosis
por: Vaz, R., et al.
Publicado: (2022)

Distinctive features of First Episode of Psychosis during the Covid-19 pandemic
por: Casanovas, F., et al.
Publicado: (2022)

Results of the Employment-Activity Program (EAP) of the PEPsNA in patients with first-episode psychosis
por: Aranguren, L., et al.
Publicado: (2022)

Use and experience with six-monthly paliperidone in the Campo de Gibraltar area. Descriptive study.
por: Gil Sánchez, C. M., et al.
Publicado: (2023)

Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice
por: Rojas, L. Gutiérrez, et al.
Publicado: (2021)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2017)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

Quality of life in patients with the first-episode psychosis
por: Usova, A., et al.
Publicado: (2021)

Clozapine in First Episode Psychosis: The best is delayed
por: Rodrigues, J. B., et al.
Publicado: (2023)

The effect of overweight on cognition in first episode of psychosis. Interaction with sex
por: Sanchez-Gistau, V., et al.
Publicado: (2023)

Multifamily therapy in first episodes of psychosis: a pilot study
por: García Del Castillo, I., et al.
Publicado: (2022)

S229. CAN LONG-ACTING INJECTABLE PALIPERIDONE DOSING BE OPTIMIZED WITH PLASMA LEVEL MEASUREMENTS?
por: Zipursky, Robert, et al.
Publicado: (2018)

F92. COMPARISONS BETWEEN CANNABIS USERS AND NON-USERS PATIENTS WITH FIRST-EPISODE PSYCHOSIS IN NEUROCOGNITIVE FUNCTIONING: A META-ANALYSIS
por: Sanchez-Gutierrez, Teresa, et al.
Publicado: (2018)

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate
por: Elefant, Erica, et al.
Publicado: (2016)

Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)
por: Segarra, R, et al.
Publicado: (2021)

Predictors of transition from paliperidone palmitate 1 and 3 months (PP1M & PPP3M) to paliperidone palmitate 6 months (PP6M)
por: Escobedo-Aedo, P. J., et al.
Publicado: (2023)

F100. FACTOR STRUCTURE OF THE CANNABIS EXPERIENCES QUESTIONNAIRE IN A FIRST-EPISODE PSYCHOSIS SAMPLE
por: Birnbaum, Michael, et al.
Publicado: (2018)

Correlation between BDNF levels and folic acid levels at baseline in drug-naïve First Episode Psychosis
por: Toll, A., et al.
Publicado: (2023)

Social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis
por: González-Ortega, I., et al.
Publicado: (2021)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

42.4 THE ENDOCANNABINOID SYSTEM IN FIRST-EPISODE PSYCHOSIS
por: Hietala, Jarmo
Publicado: (2018)

Predicting one-year outcomes in first-episode psychosis
por: Lindgren, M., et al.
Publicado: (2021)

Achievement of remission after first-episode psychosis in youth
por: Kaleda, V., et al.
Publicado: (2021)

First episode psychosis related to COVID-19 infection
por: Dhakouani, S., et al.
Publicado: (2022)

Sociodemographic characteristics of immigrants hospitalized for first episode of psychosis
por: Kabtni, W., et al.
Publicado: (2022)

Antipsychotic prescribing choices in patients with First Episode Psychosis
por: Fallon, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vk0grlqp5j9vo3cbv7t9r618sg